Topic: pneumococcal vaccine
Looking to take on global vaccine heavyweights, SutroVax revs up with Series C funding and a prominent new chairman.
Pfizer has three vaccine programs in development—and top executives have high hopes—but two key programs have competitors close behind.
Serum Institute of India plans to launch four vaccines in the coming years for pneumococcal, HPV, meningococcal and dengue.
Pfizer has relaunched its “Know Pneumonia” disease awareness campaign with a myths-and-facts approach.
Pfizer taps singer Patti LaBelle to raise awareness about risks of pneumococcal pneumonia for older adults in online campaign "All About Your Boom."
MSF's strong opposition didn't stop India's government from granting Pfizer a patent that protects Prevnar's exclusivity till 2026.
When Pfizer was gearing up to launch Prevnar 13 in adults age 50 and over, it faced a few unique challenges.
Novartis may face more furor in Korea, Astellas will develop a Prevnar rival with Affinivax, and Lilly and Chi-Med's colorectal cancer med aims for an NDA in China.
Astellas just forged a licensing deal with Affinivax to develop a pneumococcal vaccine. Their target? Pfizer’s Prevnar 13—the world’s best-selling vaccine.
Pfizer’s blockbuster pneumococcal vaccine Prevnar stumbled in fourth-quarter results released Tuesday, falling far short of Street estimates and dragging on the company’s entire vaccines unit.